Qiagen NV has a consensus price target of $37.14, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from Morgan Stanley, JP Morgan, and Citigroup on February 16, 2024, February 8, 2024, and February 8, 2024. With an average price target of $54.33 between Morgan Stanley, JP Morgan, and Citigroup, there's an implied 28.80% upside for Qiagen NV from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/16/2024 | QGEN | Buy Now | Qiagen | $42.19 | 20.9% | Morgan Stanley | Steve Beuchaw | $49.48 → $51 | Upgrade | Equal-Weight → Overweight | Get Alert |
02/08/2024 | QGEN | Buy Now | Qiagen | $42.19 | 23.27% | JP Morgan | Tycho Peterson | $50 → $52 | Maintains | Overweight | Get Alert |
02/08/2024 | QGEN | Buy Now | Qiagen | $42.19 | 42.23% | Citigroup | Patrick Donnelly | $61.86 → $60 | Maintains | Buy | Get Alert |
12/20/2023 | QGEN | Buy Now | Qiagen | $42.19 | 18.53% | JP Morgan | Tycho Peterson | $46.35 → $51.5 | Maintains | Overweight | Get Alert |
12/19/2023 | QGEN | Buy Now | Qiagen | $42.19 | 4.3% | Wells Fargo | Timothy Daley | → $45.32 | Initiates | → Equal-Weight | Get Alert |
12/13/2023 | QGEN | Buy Now | Qiagen | $42.19 | — | Wolfe Research | Doug Schenkel | — | Initiates | → Peer Perform | Get Alert |
12/07/2023 | QGEN | Buy Now | Qiagen | $42.19 | — | Goldman Sachs | Matthew Sykes | — | Upgrade | Neutral → Buy | Get Alert |
11/02/2023 | QGEN | Buy Now | Qiagen | $42.19 | -0.44% | UBS | John Sourbeer | $49.44 → $43.26 | Maintains | Neutral | Get Alert |
10/17/2023 | QGEN | Buy Now | Qiagen | $42.19 | 18.53% | JP Morgan | Tycho Peterson | $56.65 → $51.5 | Maintains | Overweight | Get Alert |
09/26/2023 | QGEN | Buy Now | Qiagen | $42.19 | 42.23% | Citigroup | Patrick Donnelly | $61.8 → $61.8 | Reiterates | Buy → Buy | Get Alert |
09/12/2023 | QGEN | Buy Now | Qiagen | $42.19 | 18.53% | Baird | Catherine Schulte | → $51.5 | Initiates | → Outperform | Get Alert |
08/09/2023 | QGEN | Buy Now | Qiagen | $42.19 | 13.78% | UBS | John Sourbeer | $51.5 → $49.44 | Maintains | Neutral | Get Alert |
02/09/2023 | QGEN | Buy Now | Qiagen | $42.19 | 23.27% | UBS | John Sourbeer | $51.5 → $53.56 | Maintains | Neutral | Get Alert |
02/09/2023 | QGEN | Buy Now | Qiagen | $42.19 | 42.23% | Citigroup | Patrick Donnelly | $56.65 → $61.8 | Maintains | Buy | Get Alert |
11/09/2022 | QGEN | Buy Now | Qiagen | $42.19 | 30.38% | Citigroup | Patrick Donnelly | $63.86 → $56.65 | Maintains | Buy | Get Alert |
12/14/2021 | QGEN | Buy Now | Qiagen | $42.19 | 42.23% | Wells Fargo | Dan Leonard | $59.74 → $61.8 | Maintains | Equal-Weight | Get Alert |
10/14/2021 | QGEN | Buy Now | Qiagen | $42.19 | — | Redburn Partners | Simon Baker | — | Initiates | → Buy | Get Alert |
07/14/2021 | QGEN | Buy Now | Qiagen | $42.19 | 17.41% | Kepler Cheuvreux | Maja Pataki | → $51.02 | Downgrade | Buy → Hold | Get Alert |
06/03/2021 | QGEN | Buy Now | Qiagen | $42.19 | 23.27% | Goldman Sachs | Matthew Sykes | → $53.56 | Initiates | → Neutral | Get Alert |
The latest price target for Qiagen (NYSE: QGEN) was reported by Morgan Stanley on February 16, 2024. The analyst firm set a price target for $51.00 expecting QGEN to rise to within 12 months (a possible 20.90% upside). 12 analyst firms have reported ratings in the last year.
The latest analyst rating for Qiagen (NYSE: QGEN) was provided by Morgan Stanley, and Qiagen upgraded their overweight rating.
The last upgrade for Qiagen NV happened on February 16, 2024 when Morgan Stanley raised their price target to $51. Morgan Stanley previously had an equal-weight for Qiagen NV.
The last downgrade for Qiagen NV happened on July 14, 2021 when Kepler Cheuvreux changed their price target from N/A to $49.53 for Qiagen NV.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Qiagen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Qiagen was filed on February 16, 2024 so you should expect the next rating to be made available sometime around February 16, 2025.
While ratings are subjective and will change, the latest Qiagen (QGEN) rating was a upgraded with a price target of $49.48 to $51.00. The current price Qiagen (QGEN) is trading at is $42.19, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.